Brewer Heineken warns British pubs to push half-pints as weight-loss drugs threaten the traditional multi-pint session
The world's second-largest brewer says GLP-1 jabs like Ozempic and Wegovy suppress the urge to drink, causing 'fullness and fewer serves'. A presentation sent to UK venues this month warns of falling visits and spending. It urges landlords to promote low- and no-alcohol drinks and pair pints with small plates. Beer generated close to £14 billion across British pubs, bars and restaurants last year.
JPMorgan research puts the number of Americans who took weight-loss medication last year at around 10 million.
Heineken says it will 'continue to monitor how these behaviours evolve in 2027'.
Diageo, the maker of Guinness, has told investors any GLP-1 hit should be 'manageable'.
More
The IndependentHeineken warns pubs to adapt as weight loss drugs shrink alcohol salesThe GuardianBoom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubsReutersEXCLUSIVE: Heineken document reveals worries over weight-loss drugs and beer salesBeverageDaily.comGLP-1 drugs put alcohol sales in focus as Heineken warns of impact - BeverageDaily.comArise NewsHeineken Warns Weight-Loss Drugs Could Threaten Beer SalesSeeking AlphaHeineken tells UK pubs to adapt as GLP-1s to put a dent in beer sales (HEINY:OTCMKTS) - Seeking AlphaYnetnewsWeight-loss drugs threaten beer sales as Heineken warns pubs of changing drinking habits - YnetnewsMezha.netHeineken warns weight-loss drug boom could cut beer sales in British pubs - Mezha.netTradingViewHeineken document reveals worries over weight-loss drugs and beer sales - TradingView
